Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes
International Health Sciences Review · 21.11.2026 · 2 (6)
DOI: 10.70164/ihsr.v2i6.281 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 21.11.2026. Verfasst von Luiza Parella Zapparoli und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have emerged as important therapeutic agents, with benefits extending beyond glycaemic control and weight reduction. This narrative review aimed to examine their pleiotropic effects across multiple organ systems, addressing cardiovascular, renal, cardiac, respiratory, hepatic, neurological and behavioural outcomes, as well as emerging safety concerns. A non-systematic literature review was conducted in PubMed/MEDLINE in November 2026, covering publications from 2018 to 2026. Twelve references were selected and qualitatively synthesized. The findings demonstrated consistent cardiovascular benefits, including reduced major adverse cardiovascular events, alongside improvements in symptoms and functional capacity in heart failure with preserved ejection fraction. Evidence also indicated kidney protection, substantial reductions in obstructive sleep apnoea severity with tirzepatide, and improvements in metabolic dysfunction-associated steatohepatitis. Conversely, potential neuroprotective effects and benefits in addictive behaviours remain preliminary and require confirmation through randomized clinical trials. Safety findings predominantly involved gastrointestinal adverse events, while a modest association with nonarteritic anterior ischaemic optic neuropathy warrants further investigation. High treatment discontinuation rates represent an important challenge to long-term effectiveness. In conclusion, incretin-based therapies demonstrate clinically relevant multisystem benefits, although their mechanisms, long-term safety and weight-independent effects require further investigation.
Zitieren
APA
Zapparoli, L. P., Pinto, A. L. D. L., Mnayarji, M. C. R., Alves, J. B. R., Rodrigues, L. D. O., Tourinho, V. P., Moreno, M. E. B., Zimmermann, A. L. G., Vinholes, B. B., Santos, C. F. D., D'Angelo, G. D. C., Almeida, H. Y. L. P. D., Gomes, L. A., Lobo, M. F. D. M. M., & Borges, I. K. (2026). Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes. International Health Sciences Review, 2(6). https://doi.org/10.70164/ihsr.v2i6.281
Vancouver
Zapparoli LP, Pinto ALDL, Mnayarji MCR, Alves JBR, Rodrigues LDO, Tourinho VP, et al. Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes. International Health Sciences Review. 2026;2(6). doi:10.70164/ihsr.v2i6.281
BibTeX
@article{Zapparoli2026,
author = {Zapparoli, Luiza Parella and Pinto, Anna Luisa de Lima and Mnayarji, Maria Clara Ribeiro and Alves, Júlia Beatriz Rodrigues and Rodrigues, Letícia de Oliveira and Tourinho, Valentina Pena and Moreno, Maria Eduarda Bellini and Zimmermann, Ana Luíza Gugelmin and Vinholes, Bibiana Born and Santos, Caterina Fonk dos and D'Angelo, Gabriel da Cruz and Almeida, Henri Yuli Lourenço Prado de and Gomes, Livia Andreassa and Lobo, Maria Fernanda de Mira Macedo and Borges, Isabela Krambeck},
title = {Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes},
journal = {International Health Sciences Review},
year = {2026},
volume = {2},
number = {6},
doi = {10.70164/ihsr.v2i6.281}
}
EUVIMED